Molecular basis of canavan’s disease: From human to mouse

Journal of Child Neurology

Volumn 18, Issue 9, 2003, Pages 604-610

  Surendran, Sankar ^a   Matalon, Kimberlee M ^a   Tyring, Stephen K ^a   Matalon, Reuben ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ASPARTOACYLASE; MYELIN; N ACETYLASPARTIC ACID; PLASMID DNA;

ADENO ASSOCIATED VIRUS; AMINO ACID BRAIN LEVEL; ARTICLE; BRAIN DEGENERATION; CANAVAN DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; ENZYME DEFECT; ENZYME DEFICIENCY; GENE MUTATION; GENE THERAPY; HUMAN; INFANT; INTRACRANIAL PRESSURE; JEW; KNOCKOUT MOUSE; MACROCEPHALY; MENTAL DEFICIENCY; MOLECULAR CLONING; MOUSE; MUSCLE HYPOTONIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN READING FRAME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPASTICITY; URINALYSIS; VIRAL GENE DELIVERY SYSTEM; WHITE MATTER;

AMIDOHYDROLASES; ANIMALS; CANAVAN DISEASE; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; PRENATAL DIAGNOSIS;

EID: 0141893608     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180090601     Document Type: Article

References (44)

1. Canavan MM: Schilder's encephalitis perioxalis diffusa. Neurology 1931;15:299-308.
2. van Bogaert L, Bertrand I: Sur une idiotie familiale avec degerescence sponglieuse de neuraxe (note preliminaire). Acta Neurol 1949;49:572-587.
3. Matalon R, Michals K, Sebasta D, et al: Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988;29:463-471.
4. Matalon R, Rady PL, Platt KA, et al: Knock out mouse for Canavan disease: A model for gene transfer to the central nervous system. J Gene Med 2000;2:165-175.
5. Buchanan DS, Davi RL: Spongy degeneration of the nervous system: A report of 4 cases with a review of the literature. Neurology 1965;15:207-222.
6. Kaul R, Balamurugan K, Gao GP, Matalon R: Canavan disease: Genomic organization and localization of human ASPA to 17p13-ter: Conservation of the ASPA gene during evolution. Genomics 1994;21:364-370.
7. Kaul R, Gao GP, Aloya M, et al: Canavan disease: Mutations among Jewish and non-Jewish patients. Am J Hum Genet 1994;55:34-41.
8. Kaul RK, Matalon R, Gao GP, et al: Spectrum of Canavan mutations among Jewish and non Jewish patients. Am J Hum Genet 1994;55(Suppl):212.
9. Kronn D, Oddoux C, Phillips J, et al: Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish individuals. Am J Hum Genet 1995;57:1250-1252.
10. Elpeleg ON, Anikster Y, Barash V, et al: The frequency of C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. Am J Hum Genet 1994;55:287-288.
11. Matalon R, Michals-Matalon K: Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Pediatr Pathol Mol Med 2000;18:471-481.
12. Matalon R, Michals-Matalon K: Molecular basis of Canavan disease. Eur J Paediatr Neurol 1998;2:69-76.
13. Matalon RM, Michals-Matalon K: Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front Biosci 2000;5:D307-D311.
14. Rushton AR, Shaywitz BA, Dumen CC, et al: Computerized tomography in the diagnosis of Canavan disease. Ann Neurol 1981; 10:57-60.
15. Brismar J, Brismar G, Gascon G, Ozand P: Canavan disease: CT and MR imaging of the brain. Am J Neurol Res 1990;11:805-810.
16. Matalon R, Michals K, Kaul R, Mafee M: Spongy degeneration of the brain, Canavan disease. Int Pediatr 1990;5:121-124.
17. Grodd W, Kragaloh-Mann I, Peterson D, et al: In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan disease) by proton spectroscopy. Lancet 1990;336:437-438.
18. Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H NMR spectroscopy in children with Canavan disease. J Magn Reson Imaging 1996;6:889-893.
19. Ory-Lavolle L, Blakely RD, Coyle JT: Neurochemical and immunochemical studies on the distribution of N-acetylaspartylglutamate and N-acetylaspartate in the rat spinal cord and some peripheral nervous tissues. J Neurochem 1987;48:895-899.
20. Sager TN, Thomsen C, Valsborg JS, et al: Astroglia contains a specific transport mechanism for N-acetyl-L-aspartate. J Neurochem 1999;73:807-811.
21. Adornato BT, O'Brien JS, Lampert PW. Cerebral spongy degeneration of infancy: A biochemical and ultrastructural study of affected twins. Neurology 1972;22:202-210.
22. Baslow MH: Molecular water pumps and the aetiology of Canavan disease: A case of the sorcerer's apprentice. J Inherit Metab Dis 1999;22:99-101.
23. Adachi M, Torii J, Schneck L, Volk BW. Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrand type). Acta Neuropathol (Berl) 1972;20:22-31.
24. Luo Y, Huang K: Spongy degeneration of the CNS in infancy. Arch Neurol 1984;41:164-170.
25. Matalon R, Michals-Matalon K: Recent advances in Canavan disease. Adv Pediatr 1999;46:493-506.
26. Kaul RK, Gao GP, Balamurugan K, Matalon R: Human aspartoacylase cDNA and mis-sense mutation in Canavan disease. Nat Genet 1993;5:118-123.
27. Matalon R, Kaul R, Michals K: Carrier rate of Canavan disease among Ashkenazi Jewish individuals. Am J Hum Genet 1994; 55:A157.
28. Shaag A, Anikster Y, Christensen E, et al: The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 1995;57:572-580.
29. Kobayashi K, Tsujino S, Ezoe T, et al: A missense mutation I143T in a Japanese patient with Canavan disease. Hum Mutat Suppl 1998;1:S308-S309.
30. Olsen TR, Tranebjaerg L, Kvittingen EA, et al: Two novel aspartoacylase (ASPA) gene missense mutations specific to Norwegian and Swedish patients with Canavan disease. J Med Genet 2002;39:e55.
31. Propheta O, Magal N, Shohat M, et al: A benign polymorphism in the aspartoacylase gene may cause misrepresentation of Canavan gene testing. Eur J Hum Genet 1998;6:635-637.
32. Alford RL, DeMarchi JM, Richards CS: Frequency of a DNA polymorphism at position Y231 in the aspartoacylase gene and its impact on DNA-based carrier testing for Canavan disease in an Ashkenazi Jewish population. Hum Mutat Suppl 1998;1:S161-S162.
33. Elpeleg ON, Shaag A, Anikster Y, Jakobs C: Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis. J Inherit Metab Dis 1994;17:664-666.
34. Matalon R, Kaul R, Gao GP: Prenatal diagnosis for Canavan disease: The use of DNA markers. J Inherit Metab Dis 1995; 18:215-217.
35. Bennett MJ, Gibson KM, Sherwood WG, et al: Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): Comparison of enzymatic and metabolite analysis. J Inherit Metab Dis 1993;16:831-836.
36. Kelley RI: Prenatal diagnosis of N-acetyl-L-aspartate in amniotic fluid. J Inherit Metab Dis 1993;16:918-919.
37. Bluml S, Seymour K, Philippart M, et al: Elevated brain water in Canavan disease: Impact of a diuretic therapy. Int Soc Magn Res 1998;171.
38. Crystal RG: Transfer of genes to humans: Early lessons and obstacles to success. Science 1995;270:404-410.
39. McDonnell TJ, Meyn RE, Robertson LE: Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 1995;6:53-60.
40. Leone P, Janson CG, Bilanuk L: Aspartoacylase gene transfer to the central nervous system with therapeutical implications for Canavan disease. Ann Neurol 2000;48:27-38.
41. Matalon R, Rady P, Surendran S, et al: Delivery of rAAV-aspartoacylase in a knock out mouse for Canavan disease, abstract. J Inherit Metab Dis 2001;24(Suppl 1): 123.
42. Latchman DS: Herpes simplex virus vectors for gene therapy. Mol Biotechnol 1994;2:179-195.
43. Wu P, Phillips M, Bui J, et al: Adenoassociated virus mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998;72:5919-5926.
44. Xiao X, Li J, McCown TJ, et al: Gene transfer by adenoassociated virus vectors into the central nervous system. Exp Neurol 1997; 144:113-124.